BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 15880133)

  • 1. Cost of autologous peripheral blood stem cell transplantation: the Norwegian experience from a multicenter cost study.
    Mishra V; Andresen S; Brinch L; Kvaløy S; Ernst P; Lønset MK; Tangen JM; Wikelund J; Flatum C; Baggerød E; Helle B; Vaaler S; Hagen TP
    Bone Marrow Transplant; 2005 Jun; 35(12):1149-53. PubMed ID: 15880133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costs of high-dose salvage therapy and blood stem cell transplantation for resistant-relapsed malignant lymphomas in a southern Italian hospital.
    Mazza P; Secondo E; Palazzo G; Amurri B; Manna N; Miloro G; Moscogiuri R
    Haematologica; 1999 Feb; 84(2):142-9. PubMed ID: 10091413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost analysis of autologous peripheral blood stem cell transplantation for multiple myeloma.
    Mishra V; Vaaler S; Brinch L
    Clin Lab Haematol; 2003 Jun; 25(3):179-84. PubMed ID: 12755795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective cost evaluation related to allogeneic haemopoietic stem cell transplantation including pretransplant procedures, transplantation and 1 year follow-up procedures.
    Mishra V; Vaaler S; Brinch L
    Bone Marrow Transplant; 2001 Dec; 28(12):1111-6. PubMed ID: 11803351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced charges and costs associated with outpatient autologous stem cell transplantation.
    Meisenberg BR; Ferran K; Hollenbach K; Brehm T; Jollon J; Piro LD
    Bone Marrow Transplant; 1998 May; 21(9):927-32. PubMed ID: 9613786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results.
    Elting LS; Shih YC; Stiff PJ; Bensinger W; Cantor SB; Cooksley C; Spielberger R; Emmanoulides C
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):806-13. PubMed ID: 17580258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thoracic aortic aneurysm repair. Direct hospital cost and Diagnosis Related Group reimbursement.
    Mishra V; Geiran O; Krohg-Sørensen K; Andresen S
    Scand Cardiovasc J; 2008 Feb; 42(1):77-84. PubMed ID: 18273734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis.
    Ghatnekar O; Alvegård T; Conradi N; Lenhoff S; Mellqvist UH; Persson U; Löthgren M
    Clin Ther; 2008 Sep; 30(9):1704-13. PubMed ID: 18840377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of chemotherapy on the mobilisation, harvest and economic costs of autologous peripheral stem cell transplantation in patients with multiple myeloma.
    Jerjis S; Croockewit S; Preijers F; Schaap N; De Witte T
    Leuk Lymphoma; 2000 May; 37(5-6):551-60. PubMed ID: 11042515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost comparative study of autologous peripheral blood progenitor cells (PBPC) and bone marrow (ABM) transplantations for non-Hodgkin's lymphoma patients.
    Woronoff-Lemsi MC; Arveux P; Limat S; Deconinck E; Morel P; Cahn JY
    Bone Marrow Transplant; 1997 Dec; 20(11):975-82. PubMed ID: 9422478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Necessary harmonization of health cost assessment. Autologous peripheral blood progenitor cell transplantation in France].
    Perrier L; Sebban C; Philip I; Standaert B; Morelle M; Latour JF; Biron P; Philip T
    Rev Epidemiol Sante Publique; 2002 Sep; 50(4):393-403. PubMed ID: 12442056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-hospital complications of autologous hematopoietic stem cell transplantation for lymphoid malignancies: clinical and economic outcomes from the Nationwide Inpatient Sample.
    Jones JA; Qazilbash MH; Shih YC; Cantor SB; Cooksley CD; Elting LS
    Cancer; 2008 Mar; 112(5):1096-105. PubMed ID: 18286506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD34+ cell dose predicts costs after autologous peripheral blood stem cell transplantation for breast cancer.
    Baron F; Copizza S; Baudoux E; Jerusalem G; Fillet G; Beguin Y
    Haematologica; 2004 Sep; 89(9):1146-8. PubMed ID: 15377481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic analysis of conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer.
    Schulman KA; Stadtmauer EA; Reed SD; Glick HA; Goldstein LJ; Pines JM; Jackman JA; Suzuki S; Styler MJ; Crilley PA; Klumpp TR; Mangan KF; Glick JH
    Bone Marrow Transplant; 2003 Feb; 31(3):205-10. PubMed ID: 12621482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.
    Vera-Llonch M; Oster G; Ford CM; Lu J; Sonis S
    J Support Oncol; 2007 May; 5(5):231-5. PubMed ID: 17564153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of actual cost, DRG-based cost, and hospital reimbursement for liver transplant patients.
    Skeie B; Mishra V; Vaaler S; Amlie E
    Transpl Int; 2002 Oct; 15(9-10):439-45. PubMed ID: 12389074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature.
    Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL
    Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EPO in combination with G-CSF improves mobilization effectiveness after chemotherapy with ifosfamide, epirubicin and etoposide and reduces costs during mobilization and transplantation of autologous hematopoietic progenitor cells.
    Hart C; Grassinger J; Andreesen R; Hennemann B
    Bone Marrow Transplant; 2009 Feb; 43(3):197-206. PubMed ID: 18806833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
    de la Rubia J; Bladé J; Lahuerta JJ; Ribera JM; Martínez R; Alegre A; García-Laraña J; Fernández P; Sureda A; de Arriba F; Carrera D; Besalduch J; García Boyero R; Palomera Bernal L; Hernández MT; García PR; Pérez-Calvo J; Alcalá A; Casado LF; San Miguel J
    Haematologica; 2006 May; 91(5):621-7. PubMed ID: 16627253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma.
    Bruns I; Steidl U; Kronenwett R; Fenk R; Graef T; Rohr UP; Neumann F; Fischer J; Scheid C; Hübel K; Haas R; Kobbe G
    Transfusion; 2006 Feb; 46(2):180-5. PubMed ID: 16441592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.